

Response to Reviewer 2 Comments

1. Summary

Thank you very much for taking the time to review this manuscript. Please find the detailed responses below and the corresponding revisions/corrections highlighted in the re-submitted files.

2. Comments

The study selected the patients receiving breast cancer surgery from August, 2019 to December, 2021 in Samsung Medical Center, can the authors start the patient's recruitment and analysis earlier than 2019, and expand the study to 2023?

Since it was concluded that National Insurance Coverage expansion and genetic counselors can improve patient outcomes, the impact of National Insurance Coverage expansion, genetic counselors, and testing rates on the prognosis of patients, such as survival and recurrence, should be investigated and deeply discussed.

3. Response

Thank you for your constructive feedback. We acknowledge the importance of investigating oncologic outcomes, and we agree with your perspective. Our study aimed to investigate the impact of NIC expansion on the increase in *BRCA1/2* mutation tests and the efficiency of these tests, concurrent with the recruitment of additional genetic counselors. Therefore, we planned to compare data from one year before and after the NIC expansion, which occurred in July 2020. However, due to the timing of additional genetic counselor recruitment in December 2020, data collection post-NIC expansion was delineated from December 2020 to December 2021.

In our study, we focused on examining the impact of NIC expansion on the increase in *BRCA1/2* mutation tests and the efficiency of these tests following the recruitment of additional genetic counselors. We conducted additional analyses to include both newly diagnosed patients and those called back for further evaluation in a cross-sectional manner.

Due to the short-term follow-up and cross-sectional nature of the study, we were unable to analyze oncologic outcomes. We appreciate your insightful comments, which provide valuable suggestions for improving our research. Moving forward, we will consider expanding the duration of the study to explore prognosis, survival rates, and recurrence rates.